Glysantis Inc. is a pre-clinical biotechnology company. The company has developed a unique, proprietary nanoparticle technology platform – NanoDendrix™ – safe, non-toxic, biodegradable and monodisperse glycogen nanoparticles extracted from sweet corn manufactured at the company’s in-house facility using a scalable process. Glysantis is leveraging the NanoDendrix platform to develop novel immune-modulatory nanoparticles and targeted drug-delivery vehicles. Key areas of focus are: virus biomanufacturing, anti-virals and immune-oncology.




Event details

Date: June 3 - June 6, 2019

Event contact

Patricia Cosgrove
Senior International Market Consultant
USA: Life Sciences